We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eco Animal Health Group Plc | EAH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 70.50 | 08:00:27 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 70.50 | 70.50 | 70.50 | 70.50 | 70.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 25/11/2024 16:50 by sharesoc We will be hosting a SIGnet follow-up meeting on December 12 at 7:00 pm to discuss and analyse the latest developments at Eko Animal Health (EAH), following their interim results presentation with Investor Meet Company on December 4.Register now: |
Posted at 11/10/2024 09:49 by boonkoh There's a good investor presentation on YouTube. Search EAH Proactive One2One.Minute 10 onwards reveals that the company thinks peak EBITDA from the vaccines could be £160m/yr. Current EBITDA is £7-8m/yr.Estimated NPV of the portfolio is £84m (vs current market cap of £48m).But the average time range to hit peak revenues is probably 2032-2035....(I hold in the Boon Fund) |
Posted at 16/8/2024 06:15 by grupo guitarlumber ECO Animal Health Group plc("ECO" or the "Company") Posting of the Annual Report and Notice of AGM ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that its Annual Report and Accounts for the year ended 31 March 2024 and Notice of Annual General Meeting ("AGM") together with Form of Proxy have today been sent to shareholders who have elected to receive hard copies by post. The Annual Report and Accounts is available on the Company's website at The Company will hold its AGM at The Grange, 100 High Street, London, N14 6BN on Thursday, 26 September 2024 at 9:00 am. A copy of the Notice of AGM and Form of Proxy will be available on the Company's website at -Ends- |
Posted at 13/11/2023 10:18 by edmonda Capital Markets Day (November 2023) - Investor Presentation (video recording now available)ECO Animal Health held a Capital Markets event focused on progress and developments in the the company's Research & Development portfolio pipeline. A series of specialist speakers took investors through six key products and the transformative impact the successful execution of their portfolio will have on their valuation. The full video has been dividend into chapters, for ease of viewing, as below: 0:00:03 Introduction and Strategy overview (Dr David Hallas, CEO) 0:04:21 R&D Overview, Strategic Approach and Portfolio (Dr. Hafid Benchaoui, Head R&D) 0:21:06 Importance of Mycoplasmas in poultry (Professor Naola Ferguson) 0:36:35 Best in Class Poultry Mycoplasma vaccines (Dr. Natalie Desloges) 0:43:10 Game changing Swine Biologicals (Dr. Brian Martinson) 0:55:37 Innovation in the treatment of swine respiratory disease (Dr. Alphonso Lopez) 1:03:33 Novel approaches to control enteric disease in poultry (Dr. Alphonso Lopez) 1:10:21 Biologicals Production (Dr. Mike Huether) 1:18:11 Portfolio Valuation & Financial analysis (Chris Wilks, CFO) 1:38:13 Summary (Dr David Hallas, CEO) 1:39:58 Questions & Answers Link here: |
Posted at 10/7/2023 10:37 by edmonda ... and just a reminder of the Investor Presentation coming up on Wednesday afternoon (12th July @ 2.30pm) - anyone interested can sign up here: |
Posted at 05/7/2023 09:35 by misca2 ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, will issue its results for the year ended 31 March 2023 on Monday 10 July 2023.Investor Presentation David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the company's FY Results for the period ended 31 March 2023. The online presentation will take place on Wednesday 12 July at 2.30pm UK time. |
Posted at 26/3/2023 10:15 by cerrito I need to remind the company how unhelpful it is for all retail investors when they say that they are trading above or below market expectations without the company specifying their understanding of what market expectations are. The more of you who can write in the better.I see that last November after the interims Singers forecast revenue for this FY at £82.4m, adjusted ebitda at £6.8m and adjusted PBT at £3.9m. No idea what their other joint broker Investec had-Incidentally good that they do not have 3 joint brokers as they have said goodbye to Peel Hunt. Singers have not put an update on Research Tree following last week's RNS and perhaps have not done one. I would encourage people to read the ED report as they have given good background info on the R&D programme and the Chinese pig market. I could not locate what they forecast before but now have £84.7m in revenue and 7m in adjusted ebitda for this current FY. They point out that the implication of this full year forecast is that the current HY is v good with £49.8m revenue-well down on the record £64m in the six months to March 2021 but if it comes to pass will be the second highest six month revenue figure of all time. ED correctly identify the Chinese risk - and indeed not sure if any of you heard the aggressive questioning of the TikTok CEO on The Hill earlier this week - both as a supplier and a customer. I continue with the view which may be Naive that the interests of EAH and the CCP for plentiful pork are aligned. There is also the product concentration risk in Aivlosin. I have mentioned before that with current exchange rates and share prices, they in theory are a takeover target. ED tells us that they are the 3rd largest player in the swine/poultry antibiotics market and the 15th largest globally in the animal health industry which is dominated by 5 global players. I see ED have come out with forecasts for the next 23/24FY with adjusted Ebitda rising to £7.8m still was down from the annus mirabilis of 20/21 when it was £17.8m. I checked the recent TR1's to see how the shareholder register has changed. We have seen Schroders go up now to 15.1pc from the 6.41pc at 30.6.22, helping Danske reduce from 6.14pc to 2. 73pc and AXA from 12.14pc to 9.9pc. I am long and badly wrong here and after this kicking of the tyres doubt if I will buy or sell if the price meanders in the 90/125p area. |
Posted at 09/1/2023 13:54 by boonkoh Still time for the read across. EAH and ANP have low investor followings, so will take time for indirect news to hit EAH. I expect a gradual decline over the next few days.Cases in China and consumer sentiment indicators look poor, and we're now only two weeks away from CNY. Looks like muted celebrations, Lower pork consumption, and a general price depression and glut to linger. |
Posted at 24/11/2022 08:03 by ga_dti Latest CEO interview discussing results highlights, improved Chinese pork prices, new product developments, new R&D collaborations and what investors can expect between now and the Full Year results - |
Posted at 21/11/2022 15:37 by edmonda Interim Results - investor presentation (28th November - save the date!)ECO Animal Health Group plc (AIM: EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to confirm that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the company's Interim Results. The online presentation will take place on Monday 28th November at 10.00am. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it. Sign up to register here: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
